RPS6KA4

Across TCGA pan-cancer cohorts, RPS6KA4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS6KA4 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPS6KA4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPS6KA4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where RPS6KA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	1.000	0.291	.001	25	view →
LUAD	DFS	Median	All	0.973	0.859	.013	13	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	12	view →
PDAC	OS	Quartile	All	0.671	0.331	.011	5	view →
CCRCC	OS	Median	All	0.911	1.000	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS6KA4–HNSC (DFS)

Open the HNSC breakdown →